Last reviewed · How we verify
NCT07068425
Longitudinal Observational Study on Immune Thrombocytopenia
trial in Immune Thrombocytopenia (ITP) in 2,000 participants. Not yet recruiting.
31 December 2035
Quick facts
| Lead sponsor | Peking University People's Hospital |
|---|---|
| Status | Not yet recruiting |
| Study type | OBSERVATIONAL |
| Enrollment | 2,000 |
| Start date | 10 July 2025 |
| Primary completion | 31 December 2035 |
| Estimated completion | 31 December 2036 |
| Sites | 1 location across China |
Conditions studied
- Immune Thrombocytopenia (ITP) — all drugs for Immune Thrombocytopenia (ITP) →
Sponsor
Peking University People's Hospital
Who can join
Eligibility, any sex, with Immune Thrombocytopenia (ITP). Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Immune Thrombocytopenia (ITP) is a bleeding disorder characterized by immune-mediated destruction and/or impaired production of platelets, leading to clinical manifestations such as petechiae, purpura, mucosal bleeding, and in severe cases, life-threatening visceral or intracranial hemorrhage. Research on the diagnosis, treatment, and prognosis of ITP is critical for improving patient outcomes and quality of life. However, most existing hematologic cohort studies are limited to single-center or small multicenter samples, lacking comprehensive, large-scale prospective investigations. To address this gap, our center plans to conduct a large-sample, combined retrospective and prospective longitudinal observational cohort study of ITP patients. The study will enroll patients to collect baseline demographic and diagnostic data, followed by longitudinal follow-up via questionnaires, telephone interviews, video consultations, online platforms, and in-person visits. Key variables including treatment regimens, comorbidities, and prognostic outcomes will be systematically recorded. Additionally, hospitalization and outpatient expenditure data will be extracted from electronic medical records. This study aims to provide high-quality real-world evidence on the epidemiology, treatment patterns, clinical outcomes, and healthcare costs of ITP patients in China, ultimately informing clinical decision-making and health policy.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Unmasking the link: pulmonary embolism risk and outcomes in adults with immune thrombocytopenia.
Zhang L, An Z, Zhao P, Huang Q, et al · · 2026 · PMID 42114623 · DOI 10.1016/j.jtha.2026.04.030
Verify or expand the search:
- PubMed search for NCT07068425
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Immune Thrombocytopenia (ITP)
Currently open trials in the same condition.
- NCT07175493 — A Study of CM336 in Patients With Relapsed or Refractory Autoimmune Cytopenia · Phase 1, PHASE2 · recruiting
- NCT07095127 — Safety, Tolerability, and Efficacy of NVG-2089 in Participants With Immune Thrombocytopenia · Phase 2 · recruiting
- NCT07065968 — The Efficacy and Safety of Combined Teriflunomide and High-dose Dexamethasone in Newly Diagnosed Primary Immune Thromboc · Phase 2 · recruiting
- NCT06973356 — Anti CD19/BCMA CAR Gene Therapy for Relapsed/Refractory Immune Thrombocytopenia · NA · recruiting
- NCT06962631 — V-IMMUNE® for Immune Thrombocytopenia · Phase 3 · recruiting
Other Peking University People's Hospital trials
Trials by the same sponsor.
- NCT07535645 — Baricitinib for Post-HSCT Persistent Thrombocytopenia · Phase 1, PHASE2 · not yet recruiting
- NCT07516002 — Immunoglobulin Efficacy and Immune Profiling in Antibody Immunodeficiency · not yet recruiting
- NCT07294339 — A Randomized Controlled Trial of Acupuncture for the Management of Hot Flashes in Patients With Hormone Receptor-Positiv · NA · not yet recruiting
- NCT07500441 — Digital PCR of CHIP and MR for MRD Monitoring After Allo-HSCT in AML · recruiting
- NCT07487883 — Cadherin 3(CDH3)-Targeted PET in Lung Malignant Tumors · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07068425 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Peking University People's Hospital
- Last refreshed: 16 July 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07068425.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing